Recombinant human erythropoietin in the treatment of infants with anaemia of prematurity

Halpérin, Daniel; Félix, Martine; Wacker, Pierre; G, Lacourt; Babel, J; Wyss, M

doi:10.1007/bf01957568

Cited by 40 publications

(18 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A similar trend in length increment was found in the 2 nd follow up (Table VII).OFC increment in both groups during the 1 st & 2 nd follow up was not statistically significant. Since the first pilot study conducted by Halpérin et al in 1990 13 numerous clinical trials have been conducted in the last two decades with a wide range of doses and administration schedules of rHuEPO to evaluate the role of it in the prevention and treatment of anemia of prematurity. This is the first documented study has been conducted in Bangladesh to evaluate the effect of short term therapy of rHuEPO in the prevention of AOP in PTVLBW neonates.…”

Section: Resultsmentioning

confidence: 99%

Effect of short term recombinant human erythropoietin (rHuEPO) therapy in the prevention of anemia of prematurity (AOP) in very low birth weight (VLBW) neonates

Yasmeen¹,

Chowdhury

Hoque

et al. 2013

Bangladesh Med Res Counc Bull

View full text Add to dashboard Cite

Premature infants especially those with birth weight <1500 g suffer from Anaemia of prematurity (AOP) and associated problems. Erythropoietin therapy is a safe effective way to prevent and to treat anaemia of prematurity. To evaluate the effect of short term administration of recombinant human erythropoietin (rHuEPO) with iron and folic acid in very low birth weight (VLBW) neonates in the prevention of anaemia of prematurity. A randomized controlled trial was carried out at Dhaka Shishu Hospital. Sixty preterm very low birth weight (PTVLBW) babies were enrolled in this study. Thirty were assigned to rHuEPO group and 30 as control. Baseline haematologic values were estimated before administration of rHuEPO. From day 7 of life rHuEPO-200

show abstract

Section: Resultsmentioning

confidence: 99%

Effect of short term recombinant human erythropoietin (rHuEPO) therapy in the prevention of anemia of prematurity (AOP) in very low birth weight (VLBW) neonates

Yasmeen¹,

Chowdhury

Hoque

et al. 2013

Bangladesh Med Res Counc Bull

View full text Add to dashboard Cite

show abstract

“…Portanto, um RN pequeno para a idade gestacional (peso desproporcionalmente baixo para a idade gestacional), teoricamente, teria um menor risco de necessitar TS. Observou-se uma estabilidade clínica, cujos critérios foram descritos em material e métodos, de todos pacientes, assim como está nas publicações da maioria dos autores [1][2][3]9,22,[27][28][29] . Apesar de alguns estudos não terem evidenciado correlação do Ht com a manifestação respirató-ria 4 , um dos critérios estabelecidos por Strauss e colaboradores 30 , em 1990, para indicar a TS seria a manutenção do Ht em 40% naqueles pacientes com doenças respiratórias.…”

Section: Discussionunclassified

“…No tocante à contagem total de leucócitos e plaquetas, não foi detectada diferença significativa entre os grupos, em nenhuma das semanas estudadas, assim como já referido por alguns autores 1,3,9,10,27,32 .…”

Section: Discussionunclassified

“…Ela é um processo autolimitado, e sua intensidade aumenta quanto mais prematuro for o RN, tornando-se, assim, menos fisiológica 7 . Os mecanismos pelos quais a anemia da prematuridade se desenvolve são coleta excessiva de sangue para exames laboratoriais, crescimento somático das crianças, menor vida média dos eritrócitos neonatais, pequena transfusão placento-fetal ao nascimento e cessação da liberação de eritropoetina (EPO) 6,[8][9][10][11] . Vários estudos encontraram, neste período, concentrações séricas de EPO inapropriadamente baixas 5,7,12 .…”

Section: Introductionunclassified

See 1 more Smart Citation

The effect of recombinant human erythropoietin on the treatment of anemia of prematurity

Rocha¹,

Benjamin²,

Procianoy³

2001

J Pediatr (Rio J)

View full text Add to dashboard Cite

Objective: to assess the efficacy of erythropoietin in the prevention and treatment of anemia of prematurity, correlating the use of this drug with weight gain, length, and head circumference and comparing two administration schemes of he same weekly dose: daily use and twice a week.Methods: the study comprised 42 premature newborns with gestational age up to 33 weeks, birthweight up to 1550 g, and postnatal age between 10 and 35 days. The newborns were randomized into three groups: patients in group 1 received seven daily doses of 100 U/kg erythropoietin per week; patients in group 2 received two 350 U/kg erythropoietin doses per week; and patients in group 3 did not receive the drug. Hematologic measurements, blood transfusion requirements, and growth rates were followed during therapy.Results: cases and controls did not differ with respect to weight, length, head circumference, and total time of hospital stay. At the end of the study, no significant difference was observed in the platelet count measurement means, white blood cell count, and ferritin levels in the three groups. However, the final hematocrit and hemoglobin values of patients who did not receive erythropoietin were significantly lower than those of patients who received the drug. The absolute reticulocyte count mean was significantly higher in patients who received erythropoietin after two weeks of treatment when compared with those patients who did not receive the drug. Patients in group 1 e 2 received fewer excessive transfusions (2 or more) than patients in group 3. The administration of 700 U/kg/week erythropoietin significantly reduced the number of excessive blood transfusions. There is no significant difference in blood transfusion volume between patients who received erythropoietin on a daily basis and those who received the drug twice weekly.Conclusions: the use of erythropoietin did not influence weight gain and growth. The administration of 700 U/kg/week erythropoietin in premature infants with gestational age up to 33 weeks and birthweight up to 1550 g stimulates erythropoiesis and significantly reduces excessive blood transfusion requirements. Erythropoietin showed to be a safe and well tolerated medication, with no short-term side effects in the study population.J Pediatr (Rio J) 2001; 77 (2): 75-83: erythropoietin, anemia of prematurity, transfusion, premature. ResumoObjetivos: a proposta do presente estudo foi avaliar a eficácia da eritropoetina na prevenção e tratamento da anemia da prematuridade, correlacionar o uso desta medicação com o ganho de peso, comprimento e perímetro cefálico dos pacientes. Foi realizada também uma comparação entre o uso de eritropoetina diariamente e o uso duas vezes por semana, na mesma dose semanal.Métodos: ensaio clínico que avaliou 42 recém-nascidos prematuros, com até 33 semanas de idade gestacional, peso de nascimento até 1550g e idade pós-natal entre 10 e 35 dias de vida. Os recém-nascidos foram randomizados em três grupos. Os pacientes do grupo 1 receberam 7 doses diárias, de 100U/kg c...

show abstract

“…However, on balance, it has been possible to show stimulation of erythropoiesis and a modest decrease in the number of transfusions administered. [1][2][3][4][5][6][7][8] Variability in therapy success has stemmed from the wide range of studied dosage regimens (75 to 1500 U/kg/week) as well as other factors including age at onset of therapy and dose of supplemental iron therapy.…”

Section: Introductionmentioning

confidence: 99%

Effect of Short-Term Erythropoietin Therapy in Anemic Premature Infants

et al. 2004

View full text Add to dashboard Cite

OBJECTIVE:To determine the effectiveness of a 10-day subcutaneous erythropoietin (rHuEpo) course of 300 units per kg per dose plus oral iron compared to oral iron alone in anemic infants during their convalescent phase of illness. STUDY DESIGN:Prospective, randomized trial performed at a 40-bed, teaching, referral, level III, neonatal intensive care unit. Infants with a gestational age at birth of less than 32 weeks, hematocrit of less than or equal to 28% with a corrected reticulocyte count of less than or equal to 5%, postconceptual age of less than 48 weeks or 5 months chronological age, and a diagnosis of anemia of prematurity were considered for inclusion. Major outcome parameters included hematocrit, corrected reticulocyte count and red cell transfusion requirements. RESULTS:A total of 60 infants were enrolled (n ¼ 30 per group). Infants randomized to rHuEpo had a significantly higher post-treatment hematocrit and corrected reticulocyte count than infants in the iron only group (p<0.001). There was a trend towards fewer red cell requirements in the rHuEpo group. CONCLUSIONS:The rHuEpo regimen studied here was associated with an acute improvement in hematocrit and corrected reticulocyte counts. This study did not demonstrate a statistically significant decrease in transfusion therapy, in part related to increased subsequent use of rHuEpo in the control group. Taken together, these data demonstrate that this regimen can effectively treat anemia in convalescent premature infants.

show abstract

Recombinant human erythropoietin in the treatment of infants with anaemia of prematurity

Cited by 40 publications

References 29 publications

Effect of short term recombinant human erythropoietin (rHuEPO) therapy in the prevention of anemia of prematurity (AOP) in very low birth weight (VLBW) neonates

Effect of short term recombinant human erythropoietin (rHuEPO) therapy in the prevention of anemia of prematurity (AOP) in very low birth weight (VLBW) neonates

The effect of recombinant human erythropoietin on the treatment of anemia of prematurity

Effect of Short-Term Erythropoietin Therapy in Anemic Premature Infants

Contact Info

Product

Resources

About